logo

KNSA

Kiniksa·NASDAQ
--
--(--)
--
--(--)

KNSA fundamentals

Kiniksa (KNSA) released its earnings on Oct 28, 2025: revenue was 180.86M (YoY +61.18%), beat estimates; EPS was 0.23 (YoY +227.78%), missed estimates.
Revenue / YoY
180.86M
+61.18%
EPS / YoY
0.23
+227.78%
Report date
Oct 28, 2025
KNSA Earnings Call Summary for Q3,2025
  • Revenue Growth: Q3 ARCALYST revenue up 61% YoY to $180.9M, with full-year guidance raised to $670-675M.
  • Market Penetration: 15% of 2+ recurrence patients treated, 20% scripts for first recurrence.
  • Pipeline Momentum: KPL-387 Phase II/III trial on track for 2026 readout; 300mg subQ dose validated.
  • Financial Strength: $352M cash balance, 118% YoY growth in collaboration profit.
  • Patient Retention: 45% restart rate within 8 weeks, average therapy duration 32 months.
EPS
Revenue

Revenue & Expenses

KNSA has released its 2025 Q3 earnings report, with revenue of 180.85M, reflecting a YoY change of 61.17%, and net profit of 18.43M, showing a YoY change of 245.24%. The Sankey diagram below clearly presents KNSA's revenue sources and cost distribution.

Key Indicators

Kiniksa (KNSA) key financial stats and ratios, covering profitability, financial health, and leverage.
Kiniksa (KNSA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Kiniksa (KNSA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Kiniksa (KNSA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Kiniksa (KNSA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Kiniksa (KNSA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield